News

Health Canada approves Arazlo lotion, 0.045%

Read time: 1 mins

Published:6th Aug 2021

Bausch Health,Canada, which is part of Bausch Health Companies Inc. and its dermatology division, one of the largest prescription dermatology health care businesses in Canada, announced that Health Canada has approved the Notice of Compliance (NOC) for Arazlo (tazarotene) lotion, 0.045%, for the topical treatment of acne vulgaris (common acne) in patients 10 years of age and older.

Arazlo is the first tazarotene acne treatment available in a lotion formulated with Prismatrex technology (a formulation with known hydrating and moisturizers, which may alleviate dryness of skin) and has been shown to provide strong efficacy with a good tolerability profile. Retinoids like tazarotene are a core component of acne treatment.

Condition: Acne

Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

CHMP positive recommendation for Tofidence (tocilizumab biosimilar)

Biogen Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Tofidence (tocilizumab), a biosimilar monoclonal antibody referencing Rocactemra

1 mins

Drug news

New data show Rinvoq (upadacitinib) demonstrated superiority versus Dupixent (dupilumab) across primary and all secondary endpoints in an open-label head-to-head atopic dermatitis study

AbbVie announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase IIIb/IV study that evaluated the efficacy and safety of upadacitinib (Rinvoq, 15 mg once daily starting dose and dose-adjusted based on clinical response) versus dupilumab (Dupixent, per its labeled dose) in adults and adolescents (greater than 12 years of age) with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or when use of those therapies was inadvisable

2 min

Drug news

FDA approves Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections

Utility Therapeutics received approval from the FDA for Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus

1 min

See all news